These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 20420535

  • 21. Recent developments in therapeutic cancer vaccines.
    Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T.
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [Abstract] [Full Text] [Related]

  • 22. [NY-ESO-1 and cancer immunotherapy].
    Peng JR, Leng XS.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [Abstract] [Full Text] [Related]

  • 23. Cancer immunogene therapy.
    Yoshizawa H, Kagamu H, Gejyo F.
    Arch Immunol Ther Exp (Warsz); 2001 Aug; 49(5):337-43. PubMed ID: 11798131
    [Abstract] [Full Text] [Related]

  • 24. Cancer-testis antigens in haematological malignancies.
    Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A, Lim SH.
    Br J Haematol; 2007 Mar; 136(6):769-76. PubMed ID: 17223912
    [Abstract] [Full Text] [Related]

  • 25. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.
    Siliņa K, Zayakin P, Kalniņa Z, Ivanova L, Meistere I, Endzeliņš E, Abols A, Stengrēvics A, Leja M, Ducena K, Kozirovskis V, Linē A.
    J Immunother; 2011 Jan; 34(1):28-44. PubMed ID: 21150711
    [Abstract] [Full Text] [Related]

  • 26. IL-13 receptor-directed cancer vaccines and immunotherapy.
    Nakashima H, Husain SR, Puri RK.
    Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
    [Abstract] [Full Text] [Related]

  • 27. From genomics to cancer vaccines: patient-tailored or universal vaccines?
    Nadler LM, Schultze JL.
    Curr Opin Mol Ther; 2002 Dec; 4(6):572-6. PubMed ID: 12596359
    [Abstract] [Full Text] [Related]

  • 28. 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors.
    Zhao Y, Wang Y.
    Cell Mol Immunol; 2007 Apr; 4(2):99-104. PubMed ID: 17484803
    [Abstract] [Full Text] [Related]

  • 29. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N, Zoernig I, Jäger D.
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [Abstract] [Full Text] [Related]

  • 30. Molecular pathological approaches to human tumor immunology.
    Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K, Ichimiya S, Tamura Y, Torigoe T.
    Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363
    [Abstract] [Full Text] [Related]

  • 31. Epigenetic biomarkers for human cancer: the time is now.
    Mulero-Navarro S, Esteller M.
    Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
    [Abstract] [Full Text] [Related]

  • 32. Epigenetic targets for immune intervention in human malignancies.
    Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L.
    Oncogene; 2003 Sep 29; 22(42):6484-8. PubMed ID: 14528272
    [Abstract] [Full Text] [Related]

  • 33. Current developments with peptide-based human tumor vaccines.
    Khazaie K, Bonertz A, Beckhove P.
    Curr Opin Oncol; 2009 Nov 29; 21(6):524-30. PubMed ID: 19770763
    [Abstract] [Full Text] [Related]

  • 34. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.
    Akers SN, Odunsi K, Karpf AR.
    Future Oncol; 2010 May 29; 6(5):717-32. PubMed ID: 20465387
    [Abstract] [Full Text] [Related]

  • 35. Expression, purification and characterization of the cancer-germline antigen GAGE12I: a candidate for cancer immunotherapy.
    Gjerstorff MF, Besir H, Larsen MR, Ditzel HJ.
    Protein Expr Purif; 2010 Oct 29; 73(2):217-22. PubMed ID: 20546897
    [Abstract] [Full Text] [Related]

  • 36. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D, Appel S.
    Scand J Immunol; 2013 Aug 29; 78(2):167-71. PubMed ID: 23672402
    [Abstract] [Full Text] [Related]

  • 37. Epigenetic opportunities and challenges in cancer.
    Best JD, Carey N.
    Drug Discov Today; 2010 Jan 29; 15(1-2):65-70. PubMed ID: 19897050
    [Abstract] [Full Text] [Related]

  • 38. Application of cell engineering technology to the tumour immunotherapeutic drug: a review.
    Chen ZN, Xing JL, Bian HJ, Mi L, Jiang JL.
    Cell Biol Int; 2001 Jan 29; 25(10):1013-5. PubMed ID: 11589619
    [Abstract] [Full Text] [Related]

  • 39. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
    Dakshinamurthy AG, Ramesar R, Goldberg P, Blackburn JM.
    Biotechnol J; 2008 Nov 29; 3(11):1417-23. PubMed ID: 18956367
    [Abstract] [Full Text] [Related]

  • 40. Cancer vaccines. Any future?
    Myc LA, Gamian A, Myc A.
    Arch Immunol Ther Exp (Warsz); 2011 Aug 29; 59(4):249-59. PubMed ID: 21644030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.